cidofovir + probenecid

Cidofovir + probenecid is a combination therapy used primarily for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS. Cidofovir is an antiviral nucleotide analogue that inhibits viral DNA polymerase, thereby suppressing viral replication. Probenecid, a uricosuric agent and inhibitor of organic anion transporters in renal proximal tubules, is co-administered to reduce the nephrotoxicity associated with cidofovir by limiting its uptake into renal tubular cells and enhancing its clearance. This combination does not cure CMV retinitis but helps control disease progression and reduce vision loss risk. The regimen requires careful dosing and monitoring due to potential side effects, including nephrotoxicity from cidofovir and hypersensitivity reactions from probenecid[2][3][4][5].